MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Pulmatrix General and Administrative Expenses 2011-2026 | PULM
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Pulmatrix
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.13 M | 7.78 M | 6.52 M | 6.78 M | 6.38 M | 6.89 K | 8.49 M | 7.52 M | 7.57 M | 8.02 M | 4.53 M | 1.74 M | 265 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.49 M | 6.89 K | 5.44 M |
Quarterly General and Administrative Expenses Pulmatrix
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 858 K | 1.53 M | 1.83 M | - | 2.21 M | 2 M | 1.63 M | - | 1.73 M | 1.67 M | 2.21 M | - | 1.68 M | 1.55 M | 1.97 M | - | 1.66 M | 1.56 M | 1.62 M | - | 1.78 M | 1.49 M | 2.21 M | - | 1.78 M | 3.13 M | 1.99 M | 2.05 M | 1.77 M | 2.12 M | 2.05 M | - | 2.02 M | 2.07 M | 1.64 M | - | 1.55 M | 2.21 M | 2.41 M | - | 3.12 M | 9.88 M | 1.93 M | 1.1 M | 695 K | 722 K | - | 263 K | 1.06 M | 801 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.88 M | 263 K | 1.94 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amgen
AMGN
|
7.05 B | $ 350.13 | 2.98 % | $ 188 B |  USA |
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | USA |
 |
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
527 M | $ 12.73 | 3.33 % | $ 3.99 B | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | USA |
 |
argenx SE
ARGX
|
308 M | $ 783.17 | 2.32 % | $ 25 B |  Niderland |
 |
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.48 | 8.82 % | $ 394 M |  Britain |
 |
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 24.57 | 5.59 % | $ 3.13 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | France |
 |
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 91.64 | 2.25 % | $ 27.2 B | Germany |
 |
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.82 | 1.6 % | $ 9.19 B |  Australia |
 |
Burford Capital Limited
BUR
|
99.3 M | $ 4.62 | 1.54 % | $ 742 M | Britain |
 |
CymaBay Therapeutics
CBAY
|
52 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
17.4 M | $ 2.68 | 4.28 % | $ 16.8 M | USA |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
20.6 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 3.05 | 0.66 % | $ 6.64 B | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
29.6 M | $ 3.05 | -0.5 % | $ 306 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Cerus Corporation
CERS
|
80.9 M | $ 1.93 | 4.62 % | $ 368 M | USA |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
22.5 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
84.8 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
7.72 M | - | -4.36 % | $ 27 M | USA |
 |
Cellectar Biosciences
CLRB
|
11.5 M | $ 2.83 | 2.91 % | $ 7.38 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
136 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
170 M | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Coherus BioSciences
CHRS
|
101 M | $ 1.73 | 3.59 % | $ 203 M | USA |